TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27659126

Group type: EXPERIMENTAL
Intervention: High-protein meals during dialysis (50-55 g) combined with lanthanum carbonate
Number of subjects: 110

Group type: COMPARATOR
Intervention: Low-protein meals during dialysis (<1 g)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: High-protein meals during dialysis
Number of subjects: 110

Group type: COMPARATOR
Intervention: Low-protein meals during dialysis
Number of subjects: 110
Study: 26054553

Group type: EXPERIMENTAL
Intervention: Omalizumab 150 mg
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg (GLACIAL)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study: 24982463

Group type: EXPERIMENTAL
Intervention: NCRT followed by surgery (45 Gy in 25 fractions over 5 weeks with fluorouracil 800 mg/m2 and cisplatin 75 mg/m2)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 195
Study: 22869065

Group type: EXPERIMENTAL
Intervention: GHRH (tesamorelin) 1 mg/d
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 19741312

Group type: EXPERIMENTAL
Intervention: Supervised exercise (1 hour twice a week for 12 months)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Counseling alone
Number of subjects: 36
Study: 17539946

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15866358

Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11931698

Group type: EXPERIMENTAL
Intervention: Etimicin alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Etimicin with piperacillin
Number of subjects: 10
Study: 9820740

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) based chemoradiation regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New chemotherapeutic agents (gemcitabine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative (adjuvant/neoadjuvant) chemoradiation regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More aggressive regimens than 5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-FU based chemoradiation with gemcitabine
Number of subjects: 0
Study: 8569517

Group type: EXPERIMENTAL
Intervention: Midwife-managed delivery unit
Number of subjects: 2844

Group type: COMPARATOR
Intervention: Consultant-led labour ward
Number of subjects: 2844
Study: 2705601

Group type: EXPERIMENTAL
Intervention: Handwritten thank you note at the bottom of the letter
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Personalized mailout package
Number of subjects: 604

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 604
Study: 343968

Group type: EXPERIMENTAL
Intervention: 400 mg fendosal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200 mg fendosal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 650 mg aspirin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 mg fendosal
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30084288

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 1784

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1784
Study: 27503436

Group type: EXPERIMENTAL
Intervention: Reminder phone call from a patient service coordinator 7 days prior to appointment
Number of subjects: 2247

Group type: COMPARATOR
Intervention: Usual care (automated phone call)
Number of subjects: 2247

Group type: EXPERIMENTAL
Intervention: Intervention arm (reminder phone call)
Number of subjects: 2247
Study: 24512654

Group type: EXPERIMENTAL
Intervention: Lower dose warfarin (test INR 1.5-2.0)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Standard warfarin (control INR 2.0-3.0)
Number of subjects: 375
Study: 22025011

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with flexor carpi radialis ligament reconstruction and interposition and temporary K‐wire stabilization (Group T+LRTI)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Trapeziectomy with no ligament reconstruction, no soft tissue interposition and no temporary Kirschner wire stabilization (Group T)
Number of subjects: 99
Study: 20145259

Group type: EXPERIMENTAL
Intervention: CS-8958 (5, 10, 20, 40, 80, or 120 mg single dose; 20 or 40 mg twice-daily for 3 days)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 18398475

Group type: EXPERIMENTAL
Intervention: PfCP‐2.9 vaccine (20, 50, 100, or 200 microg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (adjuvant only)
Number of subjects: 52
Study: 15743661

Group type: EXPERIMENTAL
Intervention: Audit and feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational reminder messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 12512985

Group type: EXPERIMENTAL
Intervention: 3% hydrogen peroxide bleaching gel (Rapid White)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 6% hydrogen peroxide whitening strips (Crest Whitestrips)
Number of subjects: 50
Study: 10661672

Group type: EXPERIMENTAL
Intervention: Reinforcement-based intensive outpatient treatment (RBT), n = 28
Number of subjects: 52

Group type: COMPARATOR
Intervention: Referral to community treatment resources, n = 24
Number of subjects: 52
Study: 8839908

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2, Vinblastine 6 mg/m2, Ifosfamide 3 mg/m2 i.v. on day 1 every 3 weeks (VIP)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2, Ifosfamide 3 mg/m2, Etoposide 120 mg/m2 on days 1, 2, and 3 (VIP-16)
Number of subjects: 212
Study: 1810523

Group type: EXPERIMENTAL
Intervention: Meclofenamic acid suppositories (200 mg) every 12 h during the immediate postsurgical period in gynecological patients.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Meclofenamic acid (active drug) given to pregnant women.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo given every 12 h during the immediate postsurgical period in gynecological patients.
Number of subjects: 40
Study: 6667652

Group type: EXPERIMENTAL
Intervention: Prematalac
Number of subjects: 9

Group type: COMPARATOR
Intervention: Premium
Number of subjects: 9
Study: 31881984

Group type: EXPERIMENTAL
Intervention: Early supplemental parenteral nutrition on the first day of ICU stay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving supplemental parenteral nutrition on the seventh day of ICU stay
Number of subjects: 0
Study: 29653634

Group type: COMPARATOR
Intervention: Loading dose of 80 mg atorvastatin before percutaneous coronary intervention followed by an additional dose of 80 mg 24 hours after the procedure
Number of subjects: 4200
Study: 27029553

Group type: EXPERIMENTAL
Intervention: Total knee replacement (TKR) followed by non-surgical treatment (neuromuscular exercise, education, diet, insoles, pain medication)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-surgical treatment alone
Number of subjects: 100
Study: 25734732

Group type: EXPERIMENTAL
Intervention: Scattered-site housing with Intensive Case Management (ICM) services
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Usual care (existing housing and support services)
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Scattered-site housing with ICM services
Number of subjects: 1198
Study: 22003960

Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin supplementation (0.14 + 0.006 mg daily)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 19573143

Group type: EXPERIMENTAL
Intervention: Probiotics and prebiotics
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 19
Study: 18852278

Group type: EXPERIMENTAL
Intervention: Fosamprenavir-ritonavir (FPV/r) 700/100 mg twice daily
Number of subjects: 113
Study: 15678552

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced (DCE) MRI
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: DCE MRI
Number of subjects: 25
Study: 11913610

Group type: EXPERIMENTAL
Intervention: Normotensive subjects
Number of subjects: 178

Group type: COMPARATOR
Intervention: Controlled and treated hypertensive subjects
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Untreated and uncontrolled hypertensive subjects
Number of subjects: 178
Study: 10436256

Group type: EXPERIMENTAL
Intervention: Benzoyloxymethyl-thiamine (BOM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9422174

Group type: EXPERIMENTAL
Intervention: Thiopentone therapy (Group A)
Number of subjects: 151

Group type: COMPARATOR
Intervention: No thiopentone therapy (Group B)
Number of subjects: 151
Study: 2137344

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 14
Study: 6962371

Group type: EXPERIMENTAL
Intervention: Salt-restriction group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29737226

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sublingual nitroglycerin (NTG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 49
Study: 28220279

Group type: EXPERIMENTAL
Intervention: DDDR with AV search hysteresis (n=502)
Number of subjects: 1530

Group type: COMPARATOR
Intervention: VVI programming (n=486)
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Overall study cohort (n=1461)
Number of subjects: 1530
Study: 26152298

Group type: EXPERIMENTAL
Intervention: New system of care (structured assessment and treatment algorithms)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Costs of Stroke Care Coordinator inputs
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Total health and social care costs
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Quality-adjusted life year gains
Number of subjects: 800
Study: 24042012

Group type: EXPERIMENTAL
Intervention: Strength training for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study: 21088114

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 100/50 μg bid (FP200/S100)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 μg once daily (CIC160)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19770376

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 267

Group type: COMPARATOR
Intervention: Postoperative chemoradiotherapy
Number of subjects: 267
Study: 21191076

Group type: EXPERIMENTAL
Intervention: MCC/Hib vaccine coadministered with PCV7 and MMR vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: MCC/Hib vaccine alone followed by PCV7 with MMR vaccine
Number of subjects: 0
Study: 16201128

Group type: EXPERIMENTAL
Intervention: 1-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT1 group; n = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT2 group; n = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT1 group; n = 54)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT2 group; n = 53)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Strains susceptible to metronidazole
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Strains resistant to metronidazole
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FAT1 group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FAT2 group
Number of subjects: 120
Study: 11966503

Group type: EXPERIMENTAL
Intervention: Clonidine, 0.3 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 10
Study: 9917050

Group type: EXPERIMENTAL
Intervention: TTS-scopolamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 50
Study: 7676701

Group type: EXPERIMENTAL
Intervention: Mitomycin C bound to activated carbon particles (MMC-CH) 50 mg dispersed throughout the peritoneal cavity before surgical closure
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no intraperitoneal anticancer drugs)
Number of subjects: 113
Study: 1968324

Group type: EXPERIMENTAL
Intervention: azatadine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: astemizole
Number of subjects: 56

Group type: COMPARATOR
Intervention: nothing (control)
Number of subjects: 56
Study: 7423159

Group type: EXPERIMENTAL
Intervention: Heparin (2 x 5000 units subcutaneously/day, first dose 1‐‐2 hours before surgery)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Heparin and control combined (independently of heparin administration)
Number of subjects: 41
Study: 30298667

Group type: EXPERIMENTAL
Intervention: Rituximab, a monoclonal antibody targeting CD20 B-cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily oral prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcineurin inhibitors and cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab or abatacept
Number of subjects: 0
Study: 27742802

Group type: COMPARATOR
Intervention: Cycling (CYC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Small-sided games (SSG)
Number of subjects: 9
Study: 25265392

Group type: EXPERIMENTAL
Intervention: Diet counselling aiming for 30 kCal/kg body weight/d and 1.2 g protein/kg/d, face-to-face discussions, 6 interviews during chemotherapy for 3 to 6 months.
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 336
Study: 22749425

Group type: EXPERIMENTAL
Intervention: Combined exercise intervention (resistance, flexibility, and Kegel exercises) twice a week for 12 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Kegel exercises (control group)
Number of subjects: 66
Study: 20397112

Group type: EXPERIMENTAL
Intervention: Rooibos tea
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (6% or 60 grams l(‐1))
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bottled water (placebo)
Number of subjects: 23
Study: 18545916

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 50-100 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 15
Study: 15984599

Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg once daily
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 12434607

Group type: EXPERIMENTAL
Intervention: Tight control group (using a special water manometer for cuff pressure control)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Loose control group (using no leak method of cuff inflation)
Number of subjects: 80
Study: 10608206

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg x kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg x kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Succinylcholine 1.5 mg x kg(‐1) preceded by 0.06 mg x kg(‐1) rocuronium
Number of subjects: 60
Study: 8746201

Group type: EXPERIMENTAL
Intervention: Losartan 25, 50, 100 mg
Number of subjects: 10
Study: 1675370

Group type: EXPERIMENTAL
Intervention: DDAVP administered via suction de-epithelialised skin for 4 days
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: DDAVP administered via suction de-epithelialised skin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Suction de-epithelialisation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Skin appearance post-treatment
Number of subjects: 7
Study: 7393432

Group type: EXPERIMENTAL
Intervention: Agitated depressed patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Retarded depressed patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both depressed groups
Number of subjects: 20

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study: 31781230

Group type: EXPERIMENTAL
Intervention: Succinate-based dietary supplement (SBDS; Amberen)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 29129157

Group type: EXPERIMENTAL
Intervention: Thrombectomy plus standard care
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 206
Study: 27038287

Group type: EXPERIMENTAL
Intervention: DCorig
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: DCsgn
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: DCsgn (continuous)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: DCsgn ≤ 5.373 (dichotomous)
Number of subjects: 221
Study: 25305235

Group type: EXPERIMENTAL
Intervention: Nonsurgical root canal treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single implant treatment
Number of subjects: 48
Study: 22520856

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (PUFAs) supplementation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 20337988

Group type: EXPERIMENTAL
Intervention: Cromoglycate (20 mg inhaled twice daily + before challenge tests)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg inhaled twice daily + before challenge tests)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg orally once daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (500 microg daily)
Number of subjects: 39
Study: 18034853

Group type: EXPERIMENTAL
Intervention: EMD+NBM+PRP
Number of subjects: 26

Group type: COMPARATOR
Intervention: EMD+NBM
Number of subjects: 26
Study: 16613812

Group type: EXPERIMENTAL
Intervention: L‐T4 monotherapy (Group 1, n=42)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: L‐T4 monotherapy subgroup with low‐normal TSH
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: L‐T4+L‐T3 combination therapy (Group 2, n=16)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (20 healthy women)
Number of subjects: 58
Study: 12054094

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiepileptics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional analgesics
Number of subjects: 0
Study: 10099064

Group type: EXPERIMENTAL
Intervention: 10 mg benazepril (acute dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 10 mg benazepril (daily for 1 month)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Baseline FMD
Number of subjects: 21
Study: 8147923

Group type: EXPERIMENTAL
Intervention: Reduced joint count assessment
Number of subjects: 15
Study: 2635094

Group type: EXPERIMENTAL
Intervention: One daily injection of human ultralente
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two daily injections of human ultralente
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: One daily injection of bovine ultralente
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two daily injections of bovine ultralente
Number of subjects: 20

Group type: COMPARATOR
Intervention: Human ultralente
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bovine ultralente
Number of subjects: 20
Study: 1057909

Group type: EXPERIMENTAL
Intervention: Spironolactone 400 mg/day (S400)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Spironolactone 200 mg/day (S200)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Chlorthalidone 100 mg/day (C100)
Number of subjects: 38
Study: 31126618

Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided intravenous line placement
Number of subjects: 167

Group type: COMPARATOR
Intervention: Traditional intravenous line placement
Number of subjects: 167
Study: 29144720

Group type: EXPERIMENTAL
Intervention: gammaCore adjunct to standard of care (SoC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SoC alone
Number of subjects: 0
Study: 24420651

Group type: EXPERIMENTAL
Intervention: School-based preventive intervention
Number of subjects: 1874
Study: 23579522

Group type: EXPERIMENTAL
Intervention: T4 ESB
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: T3 and T4 ESB
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: T4 ESB in association with T3 ramicotomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (T4 ESB)
Number of subjects: 90
Study: 21461352

Group type: EXPERIMENTAL
Intervention: 10-week intensified exercise training (ET)
Number of subjects: 0
Study: 19210281

Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care (PC)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 107
Study: 16887480

Group type: EXPERIMENTAL
Intervention: Anastrozole (n=3125)
Number of subjects: 6241

Group type: COMPARATOR
Intervention: Tamoxifen (n=3116)
Number of subjects: 6241
Study: 15499298

Group type: EXPERIMENTAL
Intervention: Dynotest Tg‐Plus immunoradiometric assay (IRMA)
Number of subjects: 157

Group type: COMPARATOR
Intervention: HTGK‐2 IRMA
Number of subjects: 157
Study: 11433707

Group type: EXPERIMENTAL
Intervention: recombinant human nerve growth factor (rhNGF)
Number of subjects: 1019

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1019
Study: 9562733

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (INR: 2.0‐3.0)
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Combination of acetylsalicylic acid (30-325 mg/day) plus dipyridamole (400 mg daily)
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Acetylsalicylic acid only (30-325 mg/day)
Number of subjects: 4500
Study: 7962781

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) 7.5% for 20 minutes daily for 8 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dodecyl trimethyl ammonium bromide (DTAB) 7.5% for 20 minutes daily for 8 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Potassium soap 7.5% for 20 minutes daily for 8 days
Number of subjects: 11